Home › Funds › Affinity Asset Advisors, LLC › MDGL
Affinity Asset Advisors, LLC position in MDGL
MADRIGAL PHARMACEUTICALS INC · Health Care
Affinity Asset Advisors, LLC reported holding 30,000 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$15.1M, representing 0.70% of its reported portfolio and ranking #38 among its reported holdings. Affinity Asset Advisors, LLC has disclosed MDGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's MDGL position evolved
Affinity Asset Advisors, LLC first disclosed a stake in MDGL in Q3 2023 at 85,000 shares (US$12.4M). The position peaked in Q3 2025 at 115,000 shares, worth US$52.7M. Across 13 filings, Affinity Asset Advisors, LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 30,000 shares valued at US$15.1M — a reduction of -10,000 shares quarter over quarter.. Notable position changes include a 44% increase in Q3 2025 (shares rose 27% over the following quarter), a 73% trim in Q4 2025 (shares fell 10% over the following quarter), a 77% increase in Q1 2026 (shares rose 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 85.00K | $12.41M | New |
| Q4 2023 | 100.00K | $23.14M | Add |
| Q1 2024 | 115.00K | $30.71M | Add |
| Q2 2024 | 110.00K | $30.82M | Reduce |
| Q3 2024 | 100.00K | $21.22M | Reduce |
| Q4 2024 | 82.50K | $25.46M | Reduce |
| Q1 2025 | 80.00K | $26.50M | Reduce |
| Q2 2025 | 80.00K | $24.21M | Hold |
| Q3 2025 | 115.00K | $52.75M | Add |
| Q4 2025 | 31.13K | $18.13M | Reduce |
| Q1 2026 | 55.00K | $28.79M | Add |
| Q2 2026 | 40.00K | $21.48M | Reduce |
| Q3 2026 | 30.00K | $15.12M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MDGL and 13F data
MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MDGL
- BAKER BROS. ADVISORS LP 2.14M sh · $1.15B · Q2 2026
- RTW INVESTMENTS, LP 1.99M sh · $1.07B · Q2 2026
- Janus Henderson Group 2.02M sh · $1.05B · Q1 2026
- Jupiter Topco LLC 1.94M sh · $1.04B · Q2 2026
- Avoro Capital Advisors LLC 1.83M sh · $984.41M · Q2 2026
- Paulson & Co 1.34M sh · $719.52M · Q2 2026
- PAULSON & CO. INC. 1.34M sh · $719.52M · Q2 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 337.04K sh · $169.85M · Q3 2026
- ARMISTICE CAPITAL, LLC 288.00K sh · $154.64M · Q2 2026
- Rock Springs Capital Management LP 175.00K sh · $93.97M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held MDGL?
Affinity Asset Advisors, LLC has disclosed MDGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Affinity Asset Advisors, LLC's current position in MDGL?
As of Q3 2026, Affinity Asset Advisors, LLC holds 30.00K shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $15.12M, representing 0.70% of its reported portfolio and ranking #38.
Has Affinity Asset Advisors, LLC been buying or selling MDGL?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC reduced its position in MDGL. The position peaked in Q3 2025 at 115.00K shares.
Which other funds hold MDGL?
Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Janus Henderson Group, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.